EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer

Rana R McKay iD, Shayan S Nazari, Andrew Elliott iD, Jennifer R Ribeiro iD, Brent S Rose, Pedro C Barata, Deepak Kilari, Rohan Garje, Neeraj Agarwal iD, Norm Smith, Emmanuel S Antonarakis, Aditya Bagrodia und 1 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Rana R McKay und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Urology, University of California San Diego, La Jolla, CA 92037, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Antigens, Surface, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Caris Life Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate-specific membrane antigen (PSMA; FOLH1) is a cell-surface target for diagnostics and treatment in prostate cancer. We utilized a database of molecularly-profiled prostate tumors to evaluate clinical, genomic, and immunologic correlates of high FOLH1 RNA expression. Patients and Methods Prostate cancer specimens (N = 7,082) underwent DNA/RNA sequencing and immunohistochemistry at Caris Life Sciences. FOLH1-High/Low expression was defined by upper/lower quartiles or median transcripts per million. Overall survival (OS) was calculated from insurance claims.

Results

Prostate adenocarcinoma had 2.97-fold higher FOLH1 expression compared to high-grade neuroendocrine prostate cancer (q < 0.0001). Of 7,020 adenocarcinomas, 4,464 were primary prostate samples, 828 were lymph node metastases, and 1,686 were distant metastases. FOLH1 expression varied across metastatic sites (highest in lymph node and lowest in liver; 1.2-fold difference, q < 0.05). FOLH1-High tumors were enriched in AR-V7 variants (10.1% vs 4.5%, q < 0.05) and associated with higher androgen receptor (AR) signaling (0.82 vs 0.78, q < 0.05). Conversely, FOLH1-Low tumors were enriched with FOXA1 (12.2% vs 6.4%), APC (11.4% vs 3.0%), PIK3CA (5.8% vs 2.7%), and PIK3R1 (2.6% vs 0.48%) mutations (q < 0.05). FOLH1-High tumors had a lower M1:M2 ratio, fewer Tregs and CD8+ T cells, higher immune checkpoint expression, and lower interferon signature scores. FOLH1-High primary tumors were more frequently microsatellite instability-High, tumor mutational burden-High, and PD-L1-positive. Among patients with metastatic tumors, median OS was improved in the FOLH1-High group (31.9 vs 23.3 months, P < .001).

Conclusions

This enhanced understanding of the distinct molecular and clinical profiles of FOLH1-expressing prostate cancers may inform optimization of PSMA-directed treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGlutamate Carboxypeptidase IIAntigens, SurfaceBiomarkers, TumorHumansMaleAgedMiddle AgedNeoplasm MetastasisGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

FOLH1PSMAlutetium-177 vipivotide tetraxetanmolecular profilingprostate cancertargeted therapy

Substanzen

Glutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, SurfaceBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine and Urology, University of California San Diego, La Jolla, CA 92037, United States.
  • Medical Affairs, Caris Life Sciences, Phoenix, AZ 85040, United States.
  • Department of Radiation Medicine and Applied Sciences, University of California, San Diego, San Diego, CA 92093, United States.
  • Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH 44106, United States.
  • Medical College of Wisconsin, Division of Hematology and Oncology, Milwaukee, WI 53226, United States.
  • Genitourinary Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, United States.

ORCID-Profile: Rana R McKay, Andrew Elliott, Jennifer R Ribeiro, Neeraj Agarwal, Himisha Beltran

Förderung

  • NCI NIH HHS
  • Caris Life Sciences

Zitieren

APA

McKay, R. R., Nazari, S. S., Elliott, A., Ribeiro, J. R., Rose, B. S., Barata, P. C., Kilari, D., Garje, R., Agarwal, N., Smith, N., Antonarakis, E. S., Bagrodia, A., & Beltran, H. (2025). Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyaf338

Vancouver

McKay RR, Nazari SS, Elliott A, Ribeiro JR, Rose BS, Barata PC, et al. Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer. The Oncologist. 2025. doi:10.1093/oncolo/oyaf338

BibTeX
@article{McKay2025,
  author = {McKay, Rana R and Nazari, Shayan S and Elliott, Andrew and Ribeiro, Jennifer R and Rose, Brent S and Barata, Pedro C and Kilari, Deepak and Garje, Rohan and Agarwal, Neeraj and Smith, Norm and Antonarakis, Emmanuel S and Bagrodia, Aditya and Beltran, Himisha},
  title = {Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf338}
}
Kostenlos starten →